- ►171.66.122.149 KF Rabe, S Hurd, A Anzueto, PJ Barnes, SA … - American journal of respiratory and critical care …, 2007 - 171.66.122.149 Chronic obstructive pulmonary disease (COPD) remains a major public health
problem. It is the fourth leading cause of chronic morbidity and mortality in
the United States, and is projected to rank fifth in 2020 in burden of ... Cited by 584 - Related articles - BL Direct - All 18 versions
- ►annals.org SD Aaron, KL Vandemheen, D Fergusson, F … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Treatment of moderate or severe chronic obstructive pulmonary
disease (COPD) with combinations of inhaled corticosteroids, long-acting
ß-agonists, and long-acting anticholinergic bronchodilators is common but ... Cited by 140 - Related articles - BL Direct - All 6 versions
DP Tashkin, B Celli, S Senn, D Burkhart, S … - New England Journal of Medicine, 2008 - content.nejm.org Methods In this randomized, double-blind trial, we compared 4 years of therapy
with either tiotropium or placebo in patients with COPD who were permitted to
use all respiratory medications except inhaled anticholinergic drugs. The ... Cited by 138 - Related articles - All 8 versions
- ►nih.gov RG Barr, J Bourbeau, CA Camargo Jr, FSF … - British Medical Journal, 2006 - thorax.bmj.com Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ... Cited by 104 - Related articles - BL Direct - All 9 versions
P Kardos, M Wencker, T Glaab, C Vogelmeier - American journal of respiratory and critical care …, 2007 - Am Thoracic Soc Main Results: The total number of exacerbations was 334 in the combination
therapy and 464 in the salmeterol group (p < 0.0001). The annualized rate of
moderate and severe exacerbations per patient was 0.92 in the combination ... Cited by 95 - Related articles - BL Direct - All 8 versions
- ►nih.gov SR Salpeter, NS Buckley, EE Salpeter - Journal of General Internal Medicine, 2006 - Springer BAGRO[TND: Anticholinergics and 2-agonists have generally been considered
equivalent choices for bronchodilation in chronic obstruc- tive pulmonary
disease (COPD). OBJECTIVE; To assess the safety and efficacy of ... Cited by 96 - Related articles - BL Direct - All 12 versions
- ►ersj.org.uk D Dusser, ML Bravo, P Iacono - European Respiratory Journal, 2006 - ersj.org.uk The mean±SD number of exacerbations during the past year was 2.14±1.40, the
mean weekly morning peak expiratory flow (PEF) was 259.6±96.1 L·min –1 and
the mean forced expiratory volume in one second (FEV 1 ) was 1.37±0.45 L. ... Cited by 96 - Related articles - BL Direct - All 6 versions
- ►atsjournals.org JA Wedzicha, P Calverley, TA Seemungal, G … - American journal of respiratory and critical care …, 2008 - Am Thoracic Soc Measurements and Main Results: Primary endpoint was health care utilization
exacerbation rate. Other endpoints included health status measured by St.
George's Respiratory Questionnaire (SGRQ), mortality, adverse events, and ... Cited by 81 - Related articles - BL Direct - All 12 versions
EO Denis, MD Shawn Aaron, MD Jean Bourbeau … - Can Respir J, 2007 - progettolibra.it *Member of the editorial committee 1Queen's University, Kingston; 2University of
Ottawa, Ottawa, Ontario; 3McGill University, Montreal, Quebec; 4Dalhousie
University, Halifax, Nova Scotia; 5University of Saskatchewan, Saskatoon, ... Cited by 68 - Related articles - All 18 versions
- ►utmem.edu [PDF] S Singh, YK Loke, CD Furberg - Jama, 2008 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. Cited by 69 - Related articles - All 12 versions
